Thyroid Nodule Evaluation: TI-RADS, FNA, and Bethesda Classification
Evidence-based guideline for the workup of thyroid nodules — from ACR TI-RADS sonographic risk stratification through fine-needle aspiration biopsy, Bethesda cytology interpretation, molecular testing, and surgical decision-making.
Executive Summary
Thyroid nodules are extraordinarily common — palpable in 5% of women and 1% of men, detected sonographically in 50–60% of adults — but only 5–10% harbor malignancy. The evaluation framework integrates clinical history, TSH measurement, neck ultrasound with ACR TI-RADS scoring, and selective fine-needle aspiration (FNA). FNA decisions follow size-based thresholds dependent on TI-RADS category: TR5 ≥1.0 cm, TR4 ≥1.5 cm, TR3 ≥2.5 cm. Cytology is reported using the Bethesda System, with malignancy risk ranging from 0–3% (Bethesda II benign) to 97–99% (Bethesda VI malignant). Indeterminate cytology (Bethesda III, IV) often benefits from molecular testing (Afirma GSC, ThyroSeq) to refine surgical decision-making and avoid diagnostic-only lobectomy. Surgical options range from active surveillance (microcarcinomas), thyroid lobectomy (low-risk single lesions), to total thyroidectomy with central neck dissection (high-risk or multifocal disease). Modern overdiagnosis concerns have shifted toward more conservative management of subcentimeter incidentalomas and selected papillary microcarcinomas.
S1. Epidemiology and Initial Evaluation
Thyroid nodules are among the most common clinical findings in adult primary care and otolaryngology practice. Palpable nodules are present in approximately 5% of women and 1% of men, while high-resolution ultrasound detects nodules in 50–60% of adults — the prevalence rising with age, female sex, iodine deficiency, and radiation exposure history. Despite this remarkable frequency, only 5–10% of nodules are malignant. The diagnostic and management challenge is identifying the small subset of clinically significant cancers while minimizing overdiagnosis, unnecessary surgery, and patient anxiety.
Etiology of thyroid nodules
| Type | Frequency | Notes |
|---|---|---|
| Colloid (adenomatous) nodule | 50–60% | Most common; benign hyperplastic process |
| Cystic / mixed cystic-solid | 15–20% | Pure cysts almost always benign; mixed lesions evaluated by solid component |
| Follicular adenoma | 10–15% | Benign; cytologically indistinguishable from follicular carcinoma without histology |
| Hashimoto’s thyroiditis with nodularity | 10–15% | Background autoimmune thyroiditis with regenerative nodules |
| Papillary thyroid carcinoma | 3–7% | ~85% of all thyroid cancers; well-differentiated; excellent prognosis |
| Follicular thyroid carcinoma | 1–2% | ~10% of thyroid cancers; hematogenous spread to bone/lung |
| Medullary thyroid carcinoma | 1–2% | C-cell origin; calcitonin marker; MEN2 association |
| Anaplastic thyroid carcinoma | <1% | Rare but lethal; rapidly enlarging mass; median survival <6 months |
| Lymphoma (primary thyroid) | <1% | Rare; arises in Hashimoto’s background |
| Metastasis (renal, lung, breast) | <1% | Rare; consider in known cancer with new nodule |
Risk factors for malignancy
- History of head/neck radiation (especially childhood) — strongest acquired risk factor; childhood cancer survivors highest risk
- Family history — papillary carcinoma in first-degree relatives, MEN2 syndromes (RET mutations), familial adenomatous polyposis (cribriform-morular variant), Cowden syndrome (PTEN), DICER1 syndrome
- Age extremes — children <20 years (lower nodule prevalence but higher malignancy rate) and adults >60 (more aggressive cancers when present)
- Male sex — although nodules less common, more likely malignant when present
- Rapid growth — clinically significant change over weeks-to-months
- Hoarseness or vocal changes — may indicate recurrent laryngeal nerve involvement
- Dysphagia or dyspnea — extrathyroidal extension or large goiter
- Cervical lymphadenopathy — particularly central compartment or jugular chain
- Fixation to surrounding tissues — hard nodule that does not move with swallowing
Initial workup
| Test | Purpose | Indications |
|---|---|---|
| TSH | Determine thyroid function status | All patients with thyroid nodule |
| Free T4 / Free T3 | Confirm hyper- or hypothyroidism if TSH abnormal | Abnormal TSH |
| Anti-TPO, anti-TG antibodies | Diagnose Hashimoto’s thyroiditis | Hypothyroidism, multinodular gland, suspected autoimmune background |
| Calcitonin | Screen for medullary thyroid carcinoma | Routine use controversial; recommended if family history MEN2, multinodular goiter undergoing surgery |
| Thyroid ultrasound (high-frequency probe) | Characterize nodule(s), assess lymph nodes, plan FNA | All thyroid nodules |
| I-123 thyroid scintigraphy | Distinguish hot vs cold nodule when TSH suppressed | Subnormal TSH only — not for euthyroid or hypothyroid |
| Cross-sectional imaging (CT/MRI) | Substernal extension, retropharyngeal, large goiter | Selected cases; avoid iodinated contrast if RAI planned |
| FNA biopsy | Histologic diagnosis | Per TI-RADS size thresholds (S2) |
Algorithm — initial workup
S2. ACR TI-RADS Sonographic Risk Stratification
The American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS), introduced in 2017, standardized sonographic risk stratification of thyroid nodules. It assigns points across 5 sonographic categories — composition, echogenicity, shape, margin, and echogenic foci — and totals them to derive a TI-RADS level (TR1 through TR5). The TR level combined with nodule size determines whether FNA, follow-up ultrasound, or no action is recommended.
The 5 sonographic categories — point assignment
| Category | Finding | Points |
|---|---|---|
| Composition | Cystic or almost completely cystic | 0 |
| Spongiform | 0 | |
| Mixed cystic and solid | 1 | |
| Solid or almost completely solid | 2 | |
| Echogenicity | Anechoic | 0 |
| Hyperechoic or isoechoic | 1 | |
| Hypoechoic | 2 | |
| Very hypoechoic | 3 | |
| Cannot determine | 1 (default) | |
| Shape | Wider-than-tall | 0 |
| Taller-than-wide (anteroposterior > transverse) | 3 | |
| Margin | Smooth | 0 |
| Ill-defined | 0 | |
| Lobulated or irregular | 2 | |
| Extrathyroidal extension | 3 | |
| Echogenic foci | None or large comet-tail artifacts | 0 |
| Macrocalcifications | 1 | |
| Peripheral (rim) calcifications | 2 | |
| Punctate echogenic foci (microcalcifications) | 3 |
TR level assignment and FNA thresholds
| TR Level | Total Points | Category | FNA Threshold | Follow-up |
|---|---|---|---|---|
| TR1 | 0 | Benign | None | None required |
| TR2 | 2 | Not suspicious | None | None required |
| TR3 | 3 | Mildly suspicious | ≥2.5 cm | Follow at 1, 3, 5 years if <2.5 cm |
| TR4 | 4–6 | Moderately suspicious | ≥1.5 cm | Follow at 1, 2, 3, 5 years if <1.5 cm |
| TR5 | ≥7 | Highly suspicious | ≥1.0 cm | Follow annually × 5 years if <1.0 cm |
Suspicious lymph nodes warrant FNA at any size
Any cervical lymph node with sonographic features suggestive of metastasis (cystic change, microcalcifications, hypervascularity, loss of fatty hilum, hyperechoic foci, rounded shape) should undergo FNA regardless of size — especially in a patient with a suspicious thyroid nodule. FNA of the suspicious node and washout for thyroglobulin (Tg) measurement greatly enhances sensitivity for metastasis detection. Tg in the FNA washout fluid is highly specific for thyroid origin even in cytologically equivocal samples.
High-risk sonographic features (memory aids)
| Feature | Why it matters |
|---|---|
| Microcalcifications (punctate echogenic foci) | Psammoma bodies of papillary carcinoma; specificity 80–95% |
| Markedly hypoechoic (darker than strap muscles) | Cellular density of tumor; specificity 75–90% |
| Taller-than-wide (AP > transverse) | Growth pattern across normal tissue planes; specificity 85–95% |
| Irregular/lobulated/spiculated margin | Infiltrative growth; specificity 75–90% |
| Extrathyroidal extension | Capsular breach; high specificity for malignancy |
| Suspicious lymphadenopathy (cystic, microcalcifications, vascular) | Metastatic disease until proven otherwise |
Low-risk / benign features
- Pure cyst (anechoic, no solid component) — <1% malignancy
- Spongiform appearance (≥50% small cystic spaces) — <3% malignancy
- “Hot” nodule on radioiodine scan — 1–4% malignancy
- Background of multinodular goiter (lower risk per individual nodule, but sample largest/most suspicious)
- Comet-tail artifact (large) — colloid; benign
S3. FNA Biopsy and Bethesda Classification
Fine-needle aspiration technique
Ultrasound-guided FNA is the gold standard for cytologic diagnosis. Free-hand palpation-guided FNA is acceptable for large palpable nodules but has higher non-diagnostic rates. Standard technique:
- 25–27 gauge needle (smaller gauge = less blood contamination, fewer artifacts)
- 2–6 passes per nodule with capillary technique or syringe-aspiration; smear preparation per local pathology preference
- Rapid on-site evaluation (ROSE) by cytopathology improves adequacy rates
- Sample multiple areas of the nodule (especially solid components of mixed lesions)
- Local anesthesia not routinely required; minimal patient discomfort
- Complications rare: hematoma (small, self-limited), infection (extremely rare), transient pain, vasovagal response
- Hold antiplatelet/anticoagulant per local protocol (often not required given small needle gauge)
The Bethesda System for Reporting Thyroid Cytopathology
| Category | Diagnosis | Risk of Malignancy | Management |
|---|---|---|---|
| I | Non-diagnostic / unsatisfactory | 5–10% | Repeat FNA with US guidance in 4–12 weeks; consider on-site cytology |
| II | Benign (colloid nodule, Hashimoto’s, etc.) | 0–3% | Sonographic surveillance per TI-RADS schedule |
| III | Atypia of undetermined significance / FLUS | 10–30% | Repeat FNA, molecular testing, or diagnostic lobectomy |
| IV | Follicular neoplasm / suspicious for FN | 25–40% | Molecular testing or diagnostic lobectomy |
| V | Suspicious for malignancy | 50–75% | Lobectomy or near-total thyroidectomy |
| VI | Malignant | 97–99% | Lobectomy or total thyroidectomy ± central neck dissection |
Detail on each Bethesda category
Bethesda I — Non-diagnostic
Insufficient cellularity (typically <6 groups of well-preserved follicular cells). Causes: cyst fluid only, blood-only aspirate, scant cellularity. Repeat FNA in 4–12 weeks. If second non-diagnostic, consider diagnostic lobectomy especially if sonographically suspicious. ~50% become diagnostic on repeat.
Bethesda II — Benign
Adequate sample with benign cytology (colloid nodule, Hashimoto’s, granulomatous thyroiditis, cyst). Approximately 70% of FNA results. Sonographic surveillance per TI-RADS schedule. Repeat FNA if growth (≥20% in 2 dimensions) or new suspicious features.
Bethesda III — Atypia of Undetermined Significance / FLUS
Indeterminate category with cytologic atypia not meeting threshold for follicular neoplasm or suspicion for malignancy. Heterogeneous category. Options: repeat FNA (40–60% benign on repeat), molecular testing (Afirma GSC negative result allows surveillance), or diagnostic lobectomy.
Bethesda IV — Follicular Neoplasm / Suspicious for FN
Microfollicular pattern; cannot distinguish follicular adenoma from follicular carcinoma without histologic evaluation of capsular and vascular invasion. ~25–40% are malignant. Options: molecular testing or diagnostic lobectomy. The Hürthle cell variant (now called oncocytic neoplasm) carries similar management.
Bethesda V — Suspicious for Malignancy
Cytologic features suggestive but not diagnostic of malignancy (e.g., suspicious for papillary carcinoma but lacking 2 of 3 cardinal features: nuclear grooves, intranuclear pseudoinclusions, optically clear nuclei). Surgical management: lobectomy if low-risk, total thyroidectomy if high-risk features.
Bethesda VI — Malignant
Diagnostic of papillary carcinoma, medullary carcinoma, anaplastic carcinoma, lymphoma, or metastasis. Surgical management based on tumor type, size, extent, and ATA risk stratification.
When to refer to endocrine surgery / otolaryngology
Refer to endocrine surgery or head and neck oncologic surgery for: Bethesda V or VI cytology; Bethesda III/IV with positive molecular testing; suspicious lymphadenopathy on imaging; nodule >4 cm regardless of cytology (lobectomy considered due to false-negative FNA rates); compressive symptoms (dysphagia, dyspnea, hoarseness); substernal extension; recurrent nodule after prior surgery; high suspicion despite benign cytology (clinical-cytologic discordance). High-volume surgeons (>25 thyroid surgeries/year) achieve significantly better outcomes including lower rates of recurrent laryngeal nerve injury and hypoparathyroidism.
S4. Molecular Testing and Surgical Decision-Making
Molecular testing for indeterminate cytology
Bethesda III (AUS/FLUS) and IV (follicular neoplasm) cytology results have intermediate malignancy risk (10–40%) — too high to ignore, too low to mandate surgery in all patients. Historically, diagnostic lobectomy was performed for all such patients, with 60–80% revealing benign histology — meaning many patients underwent unnecessary surgery. Molecular testing has substantially refined this decision-making.
| Test | Methodology | Performance | Use |
|---|---|---|---|
| Afirma Genomic Sequencing Classifier (GSC) | RNA-seq gene expression classifier; 10,196 genes analyzed; benign/suspicious binary call | NPV ~96%, PPV ~50% in Bethesda III/IV | Rule-out test; benign result allows surveillance |
| ThyroSeq v3 | NGS-based mutation + gene fusion + CNV + gene expression panel; 112 genes | NPV ~97%, PPV ~66% | Both rule-out and rule-in; identifies actionable mutations (BRAF, RAS, RET/PTC, PAX8/PPARG) |
| RosettaGX Reveal | microRNA classifier (24 miRNAs) | NPV ~92%, PPV ~50% | Used on cytology smears (does not require fresh tissue) |
| BRAF V600E mutation | Targeted PCR/NGS for single mutation | ~99% PPV for papillary carcinoma when positive; low sensitivity | Confirmatory rule-in test; predicts more aggressive behavior |
Insurance and cost considerations
Molecular testing costs $3000–5000 per specimen. Most commercial insurers and Medicare cover Afirma GSC and ThyroSeq for Bethesda III/IV with appropriate documentation. Cost-effectiveness analyses generally favor molecular testing when avoidance of unnecessary surgery is factored in. Discussion with patient should include test characteristics, downstream implications of results, and out-of-pocket cost.
Surgical decision-making — lobectomy vs total thyroidectomy
The 2015 ATA guidelines significantly broadened indications for thyroid lobectomy (vs total thyroidectomy) in low-risk thyroid cancer. Key principles:
| Scenario | Recommended Surgery |
|---|---|
| Bethesda VI papillary carcinoma, <1 cm, no extrathyroidal extension, no lymph nodes, no high-risk features | Lobectomy or active surveillance (selected cases) |
| Bethesda VI papillary carcinoma, 1–4 cm, intrathyroidal, no nodes, no high-risk features | Lobectomy (preferred) or total thyroidectomy |
| Bethesda VI, >4 cm OR extrathyroidal extension OR clinical N1 disease | Total thyroidectomy ± central neck dissection |
| Bethesda VI with distant metastases, high-grade histology, or anaplastic features | Total thyroidectomy + therapeutic lymph node dissection + RAI |
| Medullary thyroid carcinoma | Total thyroidectomy + central neck dissection (and lateral if N1) |
| Bethesda V (suspicious) | Lobectomy first; complete to total if histology malignant and high-risk |
| Bethesda IV with molecular high-risk mutation (BRAF, TERT) | Lobectomy if intrathyroidal <4 cm; consider total thyroidectomy if extensive |
| Bethesda IV with molecular low-risk (RAS) or benign result | Lobectomy; surveillance after benign histology |
Active surveillance for papillary microcarcinoma
Pioneered at Kuma Hospital (Japan) and validated at Memorial Sloan Kettering, active surveillance (AS) is an alternative to immediate surgery for selected low-risk papillary microcarcinomas (≤1 cm, no extrathyroidal extension, no lymph node involvement, no aggressive cytology features). Outcomes from large series:
- Tumor growth (≥3 mm in any dimension): 5–10% over 5 years
- New lymph node metastasis: 1–4% over 5 years
- Disease-specific survival: ~100% even when surgery is delayed
- Patients can transition to surgery at any time without compromised outcomes
- Avoid surveillance in young patients (<40 years), pregnant women, those with Hashimoto’s background, family history of thyroid cancer, or extrathyroidal location near critical structures
Surgical complications
| Complication | Lobectomy | Total thyroidectomy |
|---|---|---|
| Recurrent laryngeal nerve injury (transient) | 1–3% | 3–5% |
| Recurrent laryngeal nerve injury (permanent) | <0.5% | 1–2% |
| External branch superior laryngeal nerve injury | <1% | 1–2% |
| Transient hypoparathyroidism | 0% (only one lobe removed) | 20–30% |
| Permanent hypoparathyroidism | 0% | 1–4% |
| Hematoma requiring re-operation | <1% | 1–2% |
| Infection | <1% | <1% |
| Need for thyroid hormone replacement | 20–30% (TSH >5 post-op) | 100% (lifelong) |
| Rates lower at high-volume centers (>25 cases/year) | Significantly | Significantly |
S5. Special Situations and Surveillance
Pregnancy
Thyroid nodules detected during pregnancy require special considerations. TSH and ultrasound are safe; FNA is safe and preferred over delaying diagnosis. Radioiodine scintigraphy is contraindicated. If FNA reveals papillary carcinoma:
- Most well-differentiated thyroid cancers grow slowly and surgery can typically be deferred to postpartum without compromising outcomes
- If surgery is required during pregnancy, the second trimester is safest
- Levothyroxine suppression therapy is not contraindicated (continue if already on it; initiate at standard pregnancy dose)
- Postpartum reassessment with ultrasound and decision regarding surgery
Pediatric thyroid nodules
Children with thyroid nodules have a much higher rate of malignancy (~25%) compared to adults (5–10%). The ATA published separate pediatric guidelines (2015) emphasizing earlier and more aggressive workup. Key differences from adult management:
- FNA threshold lowered: any solid hypoechoic nodule, any nodule with high-risk features regardless of size
- Use ultrasound-guided FNA (palpation alone less reliable in small necks)
- Higher rate of multifocality and lymph node metastases
- Total thyroidectomy with central neck dissection often preferred over lobectomy due to higher recurrence risk
- RAI ablation in selected cases despite concerns about secondary malignancy in children
- Long-term surveillance for recurrence and treatment-related complications
Multinodular goiter
For patients with multiple nodules, FNA decisions should be guided by sonographic risk stratification of each nodule, not by overall gland size. Sample the most suspicious nodule(s) regardless of size. Avoid sampling every nodule — this unnecessarily increases anxiety and overdiagnosis. Surveillance is per the highest-risk nodule.
Family history of thyroid cancer
Familial papillary thyroid carcinoma (3+ first-degree relatives) accounts for 3–5% of papillary carcinomas. Other inherited syndromes:
- MEN2A/2B: medullary thyroid carcinoma; RET mutation; consider prophylactic thyroidectomy in early childhood (before age 5 in MEN2A, before age 1 in MEN2B)
- FAP (familial adenomatous polyposis): cribriform-morular variant of papillary carcinoma; APC mutation
- Cowden syndrome: PTEN mutation; multinodular goiter with malignancy risk
- Carney complex: PRKAR1A mutation; thyroid follicular adenomas/carcinomas
- DICER1 syndrome: multinodular goiter and rare thyroid cancers
Surveillance schedules for benign nodules
| Initial finding | Surveillance schedule | When to repeat FNA |
|---|---|---|
| TR1, TR2 nodule | None required | Only if new clinical finding |
| TR3 nodule <2.5 cm | US at 1, 3, 5 years | If growth ≥20% in 2 dimensions or new suspicious feature |
| TR4 nodule <1.5 cm | US at 1, 2, 3, 5 years | If growth or new suspicious feature |
| TR5 nodule <1 cm | Annual US × 5 years | If growth or new suspicious feature |
| Bethesda II benign FNA | Per TI-RADS schedule | If growth ≥20% in 2 dimensions or new suspicious feature |
| Bethesda I (non-diagnostic) | Repeat FNA in 4–12 weeks; lobectomy if persistently non-diagnostic with suspicious features | — |
Beware “thyroid cancer epidemic” — overdiagnosis
The dramatic 3-fold rise in thyroid cancer incidence over the past 30 years has been almost entirely driven by detection of small papillary microcarcinomas (≤1 cm) on imaging — without a corresponding rise in mortality. This is a textbook overdiagnosis phenomenon. The implication: be judicious about ultrasound use in low-risk patients, follow TI-RADS-based FNA thresholds rigorously, embrace active surveillance for selected microcarcinomas, and counsel patients honestly about the indolent nature of most thyroid cancers. Not every small thyroid cancer requires aggressive surgical intervention.
Practice Insights: TI-RADS Size Thresholds, Molecular Testing for Indeterminate, Active Surveillance for Microcarcinoma
ACR TI-RADS Size Thresholds Anchor FNA Decision
in experienced hands, the FNA decision rests on ACR TI-RADS classification combined with nodule size thresholds. TR1 (benign): no FNA. TR2 (not suspicious): no FNA. TR3 (mildly suspicious): FNA if ≥2.5 cm; surveillance if 1.5-2.4 cm. TR4 (moderately suspicious): FNA if ≥1.5 cm; surveillance if 1.0-1.4 cm. TR5 (highly suspicious): FNA if ≥1.0 cm; surveillance if 0.5-0.9 cm. Below these thresholds, surveillance with serial ultrasound (12-24 months) rather than biopsy. This single framework avoids the over-biopsy era of “any nodule over 1 cm gets stuck” and reduces unnecessary procedures, with the trade-off of accepting some delayed diagnosis of low-risk microcarcinomas that have favorable natural history regardless.
Molecular Testing Rescues Indeterminate Cytology
For Bethesda III (AUS/FLUS) and Bethesda IV (FN) cytology, the established reflex is molecular testing before recommending diagnostic lobectomy. Afirma GSC (gene sequencing classifier) — high negative predictive value (~96%), benign call reliably rules out malignancy and avoids surgery. ThyroSeq v3 (next-generation sequencing panel) — both rule-in and rule-out capability via gene mutations + fusions + copy number. ThyGeNext + ThyraMIR — combined mutation + microRNA testing. Molecular testing reduces diagnostic surgery rates from roughly 75% (historical) to 30-40% for Bethesda III, and roughly 95% to 50% for Bethesda IV. The cost is offset by avoided unnecessary surgeries and surgical complications.
Active Surveillance for Selected Low-Risk Papillary Microcarcinoma
For papillary thyroid microcarcinoma (≤1 cm) without high-risk features (no extrathyroidal extension, no lymph node metastasis, not posterior subcapsular near recurrent laryngeal nerve, not adjacent to trachea), active surveillance is emerging as an alternative to immediate surgery. Kuma Hospital and Memorial Sloan Kettering data: roughly 90% of these microcarcinomas remain stable or grow <3 mm over 10 years; the small percentage that progress are still curable with delayed surgery without compromising long-term survival. the patients selection: age 60+ (more conservative below this), small tumor (≤1 cm), no high-risk imaging features, patient understanding and acceptance, reliable follow-up. Serial ultrasound every 6 months × 2 years, then annually.
Bethesda Classification Drives Next Steps
The Bethesda cytology classification translates the FNA result into a treatment recommendation: I (non-diagnostic, 5-10%) — repeat FNA within 3 months. II (benign, 60-70%) — surveillance ultrasound 12-24 months. III (AUS/FLUS, 5-15%) — molecular testing first; if benign call → surveillance; if suspicious → repeat FNA or lobectomy. IV (FN, 5-10%) — molecular testing; if benign → surveillance; if suspicious → diagnostic lobectomy. V (suspicious for malignancy, 3-5%) — total thyroidectomy or lobectomy depending on risk and patient preference. VI (malignant, 5%) — total thyroidectomy ± central neck dissection.
Illustrative Scenario
A patient in their forties was found to have a 2.1 cm thyroid nodule on screening neck ultrasound. ACR TI-RADS scoring: solid composition (2), hypoechoic (2), wider-than-tall (0), smooth margin (0), no echogenic foci (0) — total 4 points, TR4 (moderately suspicious). Size 2.1 cm exceeds 1.5 cm FNA threshold for TR4, so FNA performed. Cytology: Bethesda III (AUS/FLUS) — atypical follicular cells with mild architectural and nuclear atypia. Rather than proceeding to diagnostic lobectomy, the treating clinicians sent ThyroSeq v3 molecular testing on the FNA sample — returned benign with no driver mutations. Patient avoided surgery and was placed on surveillance ultrasound at 12 months. Two-year follow-up showed stable nodule with no change in size or sonographic features.
Practice Pattern Refinements vs Standard Algorithm
- ACR TI-RADS size thresholds anchor FNA selection. TR3 ≥2.5 cm, TR4 ≥1.5 cm, TR5 ≥1.0 cm trigger biopsy. Below thresholds: surveillance, not biopsy. Avoids over-biopsy era.
- Molecular testing reflex for Bethesda III and IV cytology. Afirma GSC, ThyroSeq v3, or ThyGeNext+ThyraMIR. Reduces diagnostic surgery rates from ~75% to ~30-40% (Bethesda III) and from ~95% to ~50% (Bethesda IV). Documented benign call → surveillance.
- Active surveillance for selected low-risk papillary microcarcinoma. ≤1 cm, no high-risk features, age ≥60 (preferred), reliable follow-up, patient acceptance. Serial ultrasound q6 mo × 2 years, then annually. Convert to surgery if growth >3 mm, new high-risk feature, or patient preference change.
- Total thyroidectomy not always required for low-risk PTC. Lobectomy is acceptable for differentiated thyroid cancer ≤4 cm, intrathyroidal, no extrathyroidal extension, no clinical lymph node involvement (per ATA 2015 guidelines). Avoids lifelong thyroid hormone replacement in this subgroup.
S6. Pearls, Pitfalls, and FAQ
Pearl 1 — Order TSH first, then ultrasound
Always check TSH before ordering thyroid scintigraphy. If TSH is suppressed, the nodule may be autonomously hyperfunctioning (“hot”), with malignancy risk only 1–4% — FNA is generally not needed. Scintigraphy with euthyroid TSH is wasteful and provides no actionable information beyond what ultrasound already shows. The TSH check costs $10 and saves both unnecessary radiation and unnecessary FNAs.
Pitfall 1 — Biopsying every nodule in a multinodular goiter
The instinct to “FNA everything” in a multinodular goiter is wrong. Apply TI-RADS to each nodule individually and biopsy only those meeting size thresholds for their TR level — typically 1 to 3 nodules out of 10+. Biopsying small benign-appearing nodules increases procedure burden, anxiety, and risk of indeterminate cytology requiring unnecessary surgery. Sample the worst-looking nodule(s), not all of them.
Pearl 2 — Molecular testing rescues many indeterminate cytologies
For Bethesda III (AUS/FLUS) and IV (follicular neoplasm), molecular testing (Afirma GSC, ThyroSeq) can avoid 50–60% of diagnostic lobectomies. The negative predictive value is ~96% — a benign molecular result effectively reclassifies the nodule as benign with high confidence, allowing sonographic surveillance instead of surgery. Counsel patients on the test, cost, and downstream implications. Most insurance covers it for appropriate Bethesda categories.
Pitfall 2 — Reflexively performing total thyroidectomy for low-risk cancer
The 2015 ATA guidelines significantly liberalized lobectomy for differentiated thyroid cancer ≤4 cm without extrathyroidal extension or lymph node involvement. Total thyroidectomy commits a patient to lifelong levothyroxine, twice the surgical complication risk, and no clear oncologic advantage. For low-risk cases, lobectomy provides equivalent oncologic outcomes with substantially lower morbidity. Refer to a high-volume surgeon and follow guideline-recommended extent of surgery.
Pearl 3 — Active surveillance is reasonable for papillary microcarcinoma
Selected papillary microcarcinomas (≤1 cm, no extrathyroidal extension, no lymph node disease, away from critical structures) can be safely managed with active surveillance based on Japanese (Kuma) and US (MSK) experience. Tumor growth is slow (5–10% in 5 years), new lymph node metastases rare (1–4%), and surgery can be performed later if needed without compromised outcomes. This avoids surgical morbidity in a population with extremely indolent disease. Selection requires careful informed consent and ongoing US surveillance.
Pitfall 3 — Missing a suspicious lymph node
The ultrasound report should always document the central and lateral cervical lymph nodes alongside the thyroid nodule itself. Suspicious lymph nodes (cystic change, microcalcifications, hypervascularity, loss of fatty hilum) warrant FNA at any size — including thyroglobulin washout for highest sensitivity. A “low-risk” appearing thyroid nodule with a suspicious lymph node is a high-risk presentation requiring urgent evaluation and likely total thyroidectomy with neck dissection. Always look at the nodes, not just the nodule.
Frequently Asked Questions
- Tirzepatide: GIP/GLP-1 Dual Agonist for Diabetes and Obesity
- Amenorrhea Workup: Primary, Secondary, Hypothalamic, PCOS, and Premature Ovarian Insufficiency
- MODY and LADA: Recognizing Monogenic and Latent Autoimmune Diabetes
- Parathyroid Adenoma and Primary Hyperparathyroidism: Evaluation, Localization, and Surgical Management
- Gestational Diabetes Mellitus: Screening, OGTT Diagnosis, Glycemic Targets & Insulin
- Pituitary Incidentaloma: Workup, Surveillance, and Management